Program

Wednesday, May 9

Welcoming Remarks and Keynote Address

7:00 p.m.-8:00 p.m.

BRAF and RAS signaling in melanoma from basic to translational and clinical research
Richard M. Marais, Paterson Institute for Cancer Research, Manchester, United Kingdom

Opening Reception

8:00 p.m.-9:30 p.m.

Thursday, May 10

Continental Breakfast

7:00 a.m.-8:00 a.m.

Session 1: EGFR

Session Chairperson: Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA
8:00 a.m.-10:00 a.m.

Challenges in overcoming resistance to targeted therapies
Jeffrey A. Engelman, Massachusetts General Hospital, Boston, MA

Strategies to overcome resistance to EGFR tyrosine kinase inhibitors
Pasi A. Jänne

Mechanisms of resistance to anti-EGFR therapies in colorectal cancers
Alberto Bardelli, University of Turin, Candiolo, Italy

NKX2-1/TITF1/TTF-1-induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcimoma *
Tomoya Yamaguchi, Nagoya Unversity Graduate School of Medicine, Nagoya, Japan

Stroma-derived matrix metalloproteinase 9 (MMP9) confers resistance to anti-EGFR therapy through cell-extrinsic activation of ERBB2/ERK/JUN pathway *
Janghee Woo, Dana-Farber Cancer Institute, Boston, MA

• New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W. Clinical Cancer Research 2011;17:5530–7.
• DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance. Squatrito M, Holland EC. Cancer Research 2011;18:5945–9.

Break

10:00 a.m.-10:30 a.m.

Session 2: Breast and Prostate Cancers

Session Chairperson: Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN
10:30 a.m.-12:30 p.m.

Therapy response and resistance in mouse models of BRCA-associated breast cancer
Jos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands

PI3K inhibitors in ER+ breast cancer: Next steps
Matthew J. Ellis, Washington University Siteman Cancer Center, St. Louis, MO

Presurgical studies as a tool for discovery of mechanisms of drug resistance in breast cancer
Carlos L. Arteaga

Reciprocal feedback regulation of the PI3K and AR pathway in prostate cancer: A mechanism of innate resistance
Brett S. Carver, Memorial Sloan-Kettering Cancer Center, New York, NY

• p95HER2 and breast cancer. Arribas J, Baselga J, Pedersen K, Parra-Palau JL. Cancer Research 2011;5:1515–9.
• Targeting continued androgen receptor signaling in prostate cancer. Massard C, Fizazi K. Clinical Cancer Research 2011;12:3876–83.
• Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. Attard G, de Bono JS. Clinical Cancer Research 2011;12:3867–75.
• New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available. Abramson V, Arteaga CL. Clinical Cancer Research 2011;5:952–8.

Lunch on Own / Free Time

12:30 p.m.-2:00 p.m.

Poster Session A / Light Refreshments

2:00 p.m.-4:30 p.m.
Click here for a list of posters scheduled in this session

Session 3: Mouse Models

Session Chairperson: David A. Tuveson, CRI/Cancer Research UK, University of Cambridge, Cambridge, United Kingdom
4:30 p.m.-6:30 p.m.

Developing therapeutics in mice with ductal pancreatic cancer
David A. Tuveson

Resistance to targeted therapies in mouse models of lung cancer
Katerina A Politi, Yale University, New Haven, CT

Targeting PI3K in cancer: Mechanistic insights from genetic mouse models
Jean J. Zhao, Dana-Farber Cancer Institute, Boston, MA

Patient derived BRCA1-deficient triple-negative breast cancer xenografts develop resistance to DNA damaging agents via genetic and epigenetic mechanisms *
Petra ter Brugge, Netherlands Cancer institute, Amsterdam, The Netherlands

Incomplete inhibition of phosphorylation of 4EBP1 is a mechanism for KRAS driven resistance to the ATP-competitive mTOR inhibitor PP242 in colorectal cancer *
Gregory S. Ducker, University of California, Berkeley, CA

Dinner on Own / Evening Off

6:30 p.m.-

Friday, May 11

Continental Breakfast

7:00 a.m.-8:00 a.m.

Session 4: Raf/MEK

Session Chairperson: Meenhard Herlyn, The Wistar Institute, Philadelphia, PA
8:00 a.m.-10:00 a.m.

Novel mechanisms of resistance in BRAF-mutant melanoma
Poulikos I. Poulikakos, Memorial Sloan-Kettering Cancer Center, New York, NY

BRAF and MEK resistance in melanoma
Meenhard Herlyn

Selective BRAF inhibitors induce bypass mechanisms within the MAP kinase pathway and beyond
Keith T. Flaherty, Massachusetts General Hospital, Boston, MA

The MEK network as a target for combination therapies
W. Michael Korn, University of California, San Francisco, CA

• Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Villanueva J, Vultur A, Herlyn M. Cancer Research 2011;23:7137–40.

Break

10:00 a.m.-10:30 a.m.

Session 5: Clinical Trial Design and Regulatory Issues

Session Chairperson: Mace L. Rothenberg, Pfizer, New York, NY
10:30 a.m.-12:30 p.m.

Preemptive or reactive? Drug development strategies in cancers resistant to targeted agents
Mace L. Rothenberg

Using molecular profiling strategies in clinical trials to understand resistance mechanisms in the era of personalized cancer medicine
Lillian L. Siu, University Health Network Ontario Cancer Institute, Toronto, ON, Canada

Regulatory considerations in addressing resistance mechanisms
Ramzi N. Dagher, Pfizer, Groton, CT

Lunch on Own / Free Time

12:30 p.m.-2:30 p.m.

Session 6: Strategies to Identify Mechanisms of Resistance: RNAi and ORFs

Session Chairperson: Thomas F. "Trey" Westbrook, Baylor College of Medicine, Houston, TX
2:30 p.m.-4:30 p.m.

Repositioning targeted therapies via forward genetics
Thomas F. “Trey” Westbrook

Finding biomarkers of response to targeted cancer drugs through functional genetics
René Bernards, Netherlands Cancer Institute, Amsterdam, The Netherlands

Functional genomics to identify cancer targets and resistance
William C. Hahn, Dana-Farber Cancer Institute, Boston, MA

Identifying mechanisms of drug resistance to MAPK pathway inhibition via genome-scale rescue screens *
Cory M. Johannessen, The Broad institute of MIT and Harvard, Cambridge, MA

Widespread potential for growth factor-driven resistance to anti-cancer kinase inhibitors *
Timothy R. Wilson, Genentech, South San Francisco, CA

Poster Session B / Reception

4:30 p.m.-7:00 p.m.
Click here for a list of posters scheduled in this session

Dinner on Own / Evening Off

7:00 p.m.-

Saturday, May 12

Continental Breakfast

7:00 a.m.-8:00 a.m.

Session 7: Immunology and Tumor Host Interactions

Session Chairperson: Joan S. Brugge, Harvard University, Boston, MA
8:00 a.m.-10:00 a.m.

Spatial and mechanical considerations for tumor therapy
Valerie M. Weaver, University of California, San Francisco, CA

Adaptive resistance of matrix-attached tumor cells
Joan S. Brugge

Enhancing the efficacy of CTLA-4 blockade
Margaret Callahan, Memorial Sloan-Kettering Cancer Center, New York, NY

Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor-resistance in EML4-ALK lung cancer cells *
Seiji Yano, Cancer Research Institute Kanazawa University, Kanazawa, Japan

• Targeting regulatory T cells in cancer. Byrne WL, Mills KH, Lederer JA, O'Sullivan GC. Cancer Research 2011;22:6915–20.
• Prospects for TIM3-targeted antitumor immunotherapy. Ngiow SF, Teng MW, Smyth MJ. Cancer Research 2011;21:6567–71.

Break

10:00 a.m.-10:15 a.m.

Session 8: Angiogenesis

Session Chairperson: Lee M. Ellis, University of Texas MD Anderson Cancer Center, Houston, TX
10:15 a.m.-12:15 p.m.

VEGF-targeted therapies: Biomarkers, biology, and understanding resistance
Lee M. Ellis

Modeling intrinsic and acquired resistance of metastatic disease to antiangiogenic drugs
Robert S. Kerbel, University of Toronto Sunnybrook Health Science Center, Toronto, ON, Canada

Markers and mechanisms of resistance to VEGF inhibitors
John V. Heymach, University of Texas MD Anderson Cancer Center, Houston, TX

Insensitivity to RAF inhibition by vemurafenib in BRAF mutant colorectal cancer by EGFR-mediated reactivation of MAPK signaling *
Ryan B. Corcoran, Massachusetts General Hospital Cancer Center, Boston, MA

Reactivation of oncogenic signaling through drug-induced feedback adaptations: Lessons from mTOR inhibitors *
Vanessa Rodrik-Outmezguine, Memorial Sloan-Kettering Cancer Center, New York, NY

• Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Lieu C, Heymach J, Overman M, Tran H, Kopetz S. Clinical Cancer Research 2011;19:6130–9.

Closing Remarks and Departure

12:15 p.m.-12:30 p.m.